Interim Report 1 January - 31 March 2025

• Continued increases in sales and gross order intake combined with lower expense level
• Significant increase in European sales organisation through co-operation with Joint Operations
• First surgeries together with Johnson & Johnson-affiliated distributors successfully completed

“It is gratifying that we continue to show growth while reporting significant improvements in costs and in results. We are undergoing a major transformation in Europe with our recent agreement with Joint Operations, which has some negative impact on sales in the short term, but we are adding a significantly larger sales force in key European markets as of April 1st. During the quarter, we achieved our best sales, order intake and customer base ever – and now, focus is on continuing on the path we have taken but at an increasingly faster pace.”, says Pål Ryfors, CEO Episurf Medical.

First quarter 2025 compared to 2024, Group
» Gross order intake amounted to SEK 3.8m (2.7)
» Group net sales amounted to SEK 4.0m (3.1)
» Order book amounted to SEK 2.4m (2.0)
» Loss for the period amounted to SEK -16.6m (-20.5)
» Earnings per share amounted to SEK -0.03 (-0.07)

Significant events during the first quarter 2025
» Episurf Medical announced that theresponse to the US FDA has been filed and addresses a request for additional information on the company’s Episealer® MTP implant
» Episurf Medical entered into a distribution agreement for several European countries with Joint Operations Ltd
» Episurf Medical announced the outcome of the exercise of warrants of series TO13B
» Episurf Medical announced that CFO Veronica Wallin will leave for a new postion

Significant events after the quarter
» No material events have occurred after the end of the period